Prelude Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Prelude Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-105,000	Closed	-$16K	–	1650
2022 Q3	$16K	Buy	+105,000	New	+$8.85M	﹤0.01%	1285
2022 Q2	–	Sell	-92,900	Closed	-$8.35M	–	2093
2022 Q1	$8.35M	Buy	+92,900	New	+$8.58M	0.24%	60
2020 Q4	–	Sell	-200	Closed	-$22K	–	2073
2020 Q3	$22K	Sell	200 -600	-75%	-$67.3K	﹤0.01%	1317
2020 Q2	$90K	Buy	+800	New	+$78.8K	0.01%	986
2019 Q4	–	Sell	-14,400	Closed	-$1.1M	–	2297
2019 Q3	$1.1M	Buy	+14,400	New	+$1.2M	0.05%	309
2019 Q1	–	Sell	-400	Closed	-$29K	–	2244
2018 Q4	$29K	Buy	+400	New	+$32.2K	﹤0.01%	1201
2016 Q1	–	Sell	-110,000	Closed	-$7.72M	–	1560
2015 Q4	$7.72M	Buy	+110,000	New	+$7.5M	1.2%	6

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Prelude Capital Management's XBI Position: Q2 2026 in Review

Prelude Capital Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 5,000 shares worth $791K. The stake represents 0.06% of the portfolio and ranks #377 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in XBI as recently as Q2 2025.

Prelude Capital Management first reported a position in XBI in Q1 2015 and has held it in 8 quarters since. The position peaked at $1.33M in Q2 2021. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Prelude Capital Management held 5,000 shares of State Street SPDR S&P Biotech ETF worth $791K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Prelude Capital Management position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.06% of Prelude Capital Management's portfolio in Q2 2026, its #377 holding.
Prelude Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and has held it in 8 quarters since.
Prelude Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.33M in Q2 2021.
934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.